Summary:
AN ADAPTIVE PHASE II/III, DOUBLE-BLIND, RANDOMIZED, PLACEBOCONTROLLED,
TWO-PART, DOSE-FINDING, MULTI-CENTER STUDY OF THE SAFETY
AND EFFICACY OF NABEN® (SODIUM BENZOATE), A D-AMINO ACID OXIDASE
INHIBITOR, AS AN ADD-ON THERAPY WITH CLOZAPINE, FOR RESIDUAL
SYMPTOMS OF REFRACTORY SCHIZOPHRENIA IN ADULTS
Qualified Participants Must:
• Male or female subjects who are between 18 and 55 years of age
Qualified Participants May Receive:
Compensation for time and travel